Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 20 versus ADDERALL XR 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 20 versus ADDERALL XR 30.
ADDERALL 20 vs ADDERALL XR 30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Adderall XR is a central nervous system (CNS) stimulant. It contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, leading to increased synaptic concentrations. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully understood but is thought to involve activation of dopaminergic and noradrenergic pathways in the prefrontal cortex.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
20-60 mg orally once daily in the morning; start at 20 mg once daily, titrate by 10 mg weekly based on tolerability and response.
None Documented
None Documented
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
The terminal elimination half-life is 10–13 hours for dextroamphetamine (the more active enantiomer) in adults; for the racemic mixture (dextroamphetamine/amphetamine), the half-life is shorter (6–8 hours) due to differential metabolism. Clinical context: Steady-state achieved within 2–3 days; once-daily dosing is sufficient.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Renal: approximately 90% (30–40% unchanged, remainder as metabolites including dehydroamphetamine and hydroxylated metabolites). Fecal: <4%. Biliary: minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant